Company intelligence / Profile preview
Anokion
Lausanne, Switzerlandbioalps.org ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Positive symptom data from Phase 2 trial of KAN-101 for celiac disease announced in January 2025. KAN-101 demonstrated clinically meaningful effects across multiple symptoms following gluten challenge. ANK-700 for multiple sclerosis is in Phase 1 development.
- Therapeutic areas
- GastroenterologyEndocrinologyNeurologyImmunology
- Modalities
- Immune tolerance therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer Ignite
Beyond the preview
Go deeper on Anokion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anokion.